Table 1.

Tumour characteristics, treatment descriptions and follow-up

Patient number	Previous pneumonectomy TNM stage	Initial treatment	New lesion (Ø cm)a	Fractions × Gy	BED Gy 10b	BED Gy 3c	PTV (cm3)d	Local failure	Follow-up
1	T2 N0	P	1	1 × 25 Gy	87.5	233	2.3	20 months	Dead owing to local progression and distant metastases at 32 months
2	T3 N0	P	4.5	3 × 10 Gy	60	130	101.2	10 months	Dead owing to local progression at 25 months
3	T2 N2, T1 N0	Lobectomy, completion P	1.8	1 × 25 Gy	87.5	233	6.4	No	Death owing to regional and distant metastases at 32 months
4	T3 N0	P	3	1 × 25 Gy	87.5	233	24.4	no	Dead owing to distant metastases at 27 months
5	T2 N1	P and post-operative RT	2.2	3 × 10 Gy	60	130	20.5	no	Dead owing to intercurrent disease at 10 months
6	T2 N0	P	1.8	1 × 26 Gy	93	251	7.8	19 months	Dead owing to local progression at 34 months
7	T2 N2	P and post-operative RT	1.8	1 × 25 Gy	87.5	233	20.4	No	Alive without disease at 33 months
8	T2 N0	P	2.8	3 × 15 Gy	112	270	24.6	No	Alive without disease at 31 months
9	T2 N0	P	2.1	4 × 10 Gy	80	173	25.1	No	Alive without disease at 26 months
10	T4 N0	P	3	4 × 10 Gy	80	173	20.9	No	Dead owing to distant metastases at 11 months
11	T2 N2	P and post-operative RT	3.3	4 × 10 Gy	80	173	24.1	No	Alive without disease at 11 months
12	T1 N0, T2 N1	P (synchronous tumour)	2.1	4 × 12 Gy	105.6	240	17.2	No	Alive without disease at 10 months

P, pneumonectomy; PTV, planning target volume; RT, radiotherapy.

^a(Ø cm), greatest tumour dimension.

^bBED Gy 10, biologically effective dose with assumed α/β ratio of 10 for tumour tissue.

^cBED Gy 3, biologically effective dose with assumed α/β ratio of 3 for normal tissue.

^dPTV consists of the tumour volume including all respiratory movements plus a 3- to 5-mm safety margin for RT planning.